Main > ONCOLOGY (**) > Liver Cancer *** > Treatment. > CN. B. HCC>TREAT.>PD-1 Binding MAb>

---

Inj.

CN. B. HCC>TREAT.>PD-1 Binding MAb>'s subsections
(*) CN Approval Date: 2021. 06.23.
Company
Generic Name: TislelizuMAb
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 5
Patent>UpDate: 2021. 06.22.
PD: Programmed Death
PR Web-Site
Product Web-Site

CN. B. HCC>TREAT.>PD-1 Binding MAb>'s products
This section has no products